Nuveen’s Zenas BioPharma ZBIO Stock Holding History

Nuveen’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69M	Sell	66,638 -1,132	-2%	-$22.5K	﹤0.01%	2662
2026 Q1	$1.32M	Buy	67,770 +16,920	+33%	+$380K	﹤0.01%	2452
2025 Q4	$1.85M	Buy	50,850 +30,331	+148%	+$998K	﹤0.01%	2323
2025 Q3	$456K	Sell	20,519 -11,107	-35%	-$181K	﹤0.01%	2927
2025 Q2	$306K	Hold	31,626	–	–	﹤0.01%	3045
2025 Q1	$250K	Buy	31,626 +11,717	+59%	+$91.7K	﹤0.01%	3074
2024 Q4	$163K	Buy	+19,909	New	+$311K	﹤0.01%	3235

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Nuveen's ZBIO Position: Q2 2026 in Review

Nuveen reduced its Zenas BioPharma (ZBIO) stake by 1.7% in Q2 2026, selling an estimated $22.5K and leaving 66,638 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2662.

Nuveen first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.85M in Q4 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Nuveen held 66,638 shares of Zenas BioPharma worth $1.69M as of Q2 2026.
Nuveen sold 1,132 Zenas BioPharma shares in Q2 2026, an estimated $22.5K.
Zenas BioPharma made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2662 holding.
Nuveen first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
Nuveen's Zenas BioPharma position peaked at $1.85M in Q4 2025.
144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.